Astellas and Theravance Announce Approval of VIBATIV TM ... - Market Wire (press release) PDF Print
Market Wire (press release)New onset or worsening renal impairment occurred in patients who received VIBATIV. Renal adverse events were more likely to occur in patients with baseline ...Astellas and Theravance Announce Approval of VIBATIV(TM) in Canada

... read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.